MA24215A1 - Composes inhibiteurs de squalene-synthetase - Google Patents
Composes inhibiteurs de squalene-synthetaseInfo
- Publication number
- MA24215A1 MA24215A1 MA24667A MA24667A MA24215A1 MA 24215 A1 MA24215 A1 MA 24215A1 MA 24667 A MA24667 A MA 24667A MA 24667 A MA24667 A MA 24667A MA 24215 A1 MA24215 A1 MA 24215A1
- Authority
- MA
- Morocco
- Prior art keywords
- squalene
- inhibitor compounds
- synthetase inhibitor
- synthetase
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2236596P | 1996-06-20 | 1996-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA24215A1 true MA24215A1 (fr) | 1997-12-31 |
Family
ID=21809221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA24667A MA24215A1 (fr) | 1996-06-20 | 1997-06-18 | Composes inhibiteurs de squalene-synthetase |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6537987B1 (fr) |
| AP (1) | AP9701018A0 (fr) |
| AU (1) | AU2401697A (fr) |
| GT (1) | GT199700069A (fr) |
| ID (1) | ID19419A (fr) |
| MA (1) | MA24215A1 (fr) |
| TN (1) | TNSN97105A1 (fr) |
| WO (1) | WO1997048701A1 (fr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2158344T3 (es) * | 1995-09-13 | 2001-09-01 | Takeda Chemical Industries Ltd | Compuestos benzoxazepinicos, su produccion y uso como agentes reductores de lipidos. |
| US20060141036A1 (en) | 1997-12-12 | 2006-06-29 | Andrx Labs Llc | HMG-CoA reductase inhibitor extended release formulation |
| ATE320803T1 (de) * | 1998-01-28 | 2006-04-15 | Warner Lambert Co | Verfahren zur behandlung von alzheimerschen krankheit |
| US6080778A (en) | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
| US6472421B1 (en) | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
| US20040204500A1 (en) * | 2001-06-28 | 2004-10-14 | Yasuo Sugiyama | Preventives/remedies for organ functional disorders and organ dysfunction |
| AU2002348276A1 (en) | 2001-11-16 | 2003-06-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| WO2003094909A2 (fr) * | 2002-05-09 | 2003-11-20 | Enos Pharmaceuticals, Inc. | Methodes et compositions pour le traitement et pour la prevention d'une claudication intermittente ou d'une maladie d'alzheimer |
| US7371759B2 (en) | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| DE102004001871A1 (de) * | 2004-01-14 | 2005-09-01 | Bayer Healthcare Ag | Tricyclische Benzazepin-Derivate und ihre Verwendung |
| DE102004006325A1 (de) * | 2004-02-10 | 2005-08-25 | Bayer Healthcare Ag | Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung |
| US7323455B2 (en) | 2004-03-24 | 2008-01-29 | Wyeth | 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators |
| US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
| CN101035520A (zh) * | 2004-08-09 | 2007-09-12 | 武田药品工业株式会社 | Crp降低剂 |
| US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| WO2006076568A2 (fr) | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Heterocycles bicycliques servant de modulateurs au recepteur de cannabinoides |
| US7314882B2 (en) | 2005-01-12 | 2008-01-01 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| WO2006076597A1 (fr) | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Heterocycles bicycliques constituant des modulateurs des recepteurs cannabinoides |
| WO2006078697A1 (fr) | 2005-01-18 | 2006-07-27 | Bristol-Myers Squibb Company | Heterocycles bicycliques utilises comme modulateurs des recepteurs de cannabinoide |
| WO2006086464A2 (fr) | 2005-02-10 | 2006-08-17 | Bristol-Myers Squibb Company | Dihydroquinazolinones utilisees comme modulateurs de la 5ht |
| CN101277949A (zh) * | 2005-04-22 | 2008-10-01 | 阿兰托斯制药控股公司 | 二肽基肽酶-ⅳ抑制剂 |
| TW200714280A (en) * | 2005-06-01 | 2007-04-16 | Takeda Pharmaceuticals Co | Novel method of treating hyperlipidemia |
| US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| US7317012B2 (en) | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| TW200726765A (en) | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
| US7795436B2 (en) | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
| TW200730503A (en) * | 2005-10-21 | 2007-08-16 | Daiichi Seiyaku Co | Tricyclic compound |
| AR056155A1 (es) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
| US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| DE102006031176A1 (de) * | 2006-07-06 | 2008-01-10 | Bayer Healthcare Ag | Substituierte Benzoxepino-isoxazole und ihre Verwendung |
| FR2904002A1 (fr) * | 2006-07-19 | 2008-01-25 | Galderma Res & Dev S N C Snc | Modulateurs de la lanosterol synthetase dans le traitement de l'acne ou de l'hyperseborrhee |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| PE20091928A1 (es) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
| BRPI1013500A2 (pt) | 2009-03-27 | 2016-04-05 | Astrazeneca Uk Ltd | métodos para previnir eventos cardiovasculares adversos maiores com inibidores de dpp-iv |
| EP2892897A1 (fr) | 2012-09-05 | 2015-07-15 | Bristol-Myers Squibb Company | Antagonistes du récepteur 1 d'hormone concentrant la mélanine de type pyrrolone ou pyrrolidinone |
| US9586900B2 (en) | 2012-09-05 | 2017-03-07 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
| CN106543102B (zh) * | 2016-10-28 | 2018-09-14 | 石家庄学院 | 1,5-苯并硫氮杂卓类衍生物及其应用 |
| CA3105626A1 (fr) | 2018-07-19 | 2020-01-23 | Astrazeneca Ab | Methodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0567026B1 (fr) * | 1992-04-20 | 2003-03-26 | Takeda Chemical Industries, Ltd. | Dérivés de 4,1-benzoxazepine comme inhibiteurs de la synthétase du squalène et leur application dans le traitement d'hypercholesteremie et comme fongicides |
| EP0782451A1 (fr) * | 1994-09-20 | 1997-07-09 | Pfizer Inc. | Combinaison d'un inhibiteur d'absorption du cholesterol et d'un inhibiteur de synthese du cholesterol |
| SK158795A3 (en) * | 1994-12-23 | 1997-01-08 | Pfizer | Benzazepines and pharmaceutical compositions on their base |
| AU6944296A (en) * | 1995-09-13 | 1997-04-01 | Takeda Chemical Industries Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| ES2158344T3 (es) * | 1995-09-13 | 2001-09-01 | Takeda Chemical Industries Ltd | Compuestos benzoxazepinicos, su produccion y uso como agentes reductores de lipidos. |
| US5965553A (en) * | 1996-06-20 | 1999-10-12 | Pfizer Inc. | Squalene synthetase inhibitors |
-
1997
- 1997-05-14 US US09/202,106 patent/US6537987B1/en not_active Expired - Fee Related
- 1997-05-14 WO PCT/IB1997/000550 patent/WO1997048701A1/fr active Application Filing
- 1997-05-14 AU AU24016/97A patent/AU2401697A/en not_active Abandoned
- 1997-06-02 GT GT199700069A patent/GT199700069A/es unknown
- 1997-06-18 MA MA24667A patent/MA24215A1/fr unknown
- 1997-06-18 TN TNTNSN97105A patent/TNSN97105A1/fr unknown
- 1997-06-19 ID IDP972091A patent/ID19419A/id unknown
- 1997-06-19 AP APAP/P/1997/001018A patent/AP9701018A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2401697A (en) | 1998-01-07 |
| GT199700069A (es) | 1998-11-24 |
| AP9701018A0 (en) | 1997-07-31 |
| US6537987B1 (en) | 2003-03-25 |
| WO1997048701A1 (fr) | 1997-12-24 |
| ID19419A (id) | 1998-07-09 |
| TNSN97105A1 (fr) | 2005-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA24215A1 (fr) | Composes inhibiteurs de squalene-synthetase | |
| ID19403A (id) | Senyawa-senyawa heterosiklik | |
| ID19609A (id) | Senyawa-senyawa heterosiklik | |
| ID16152A (id) | Senyawa-senyawa triaril | |
| ID19430A (id) | Senyawa senyawa heterosiklik | |
| BR9709230A (pt) | Composto | |
| ID15904A (id) | Senyawa-senyawa tiofenopirimidina | |
| BR9710352A (pt) | Compostos piridilpirrole | |
| BR9707051A (pt) | Composto | |
| PT958287E (pt) | Inibidores de sulfamida-metaloprotease | |
| ATE262512T1 (de) | Arylalkanoylpyridazine | |
| ATE208773T1 (de) | Chinoxalindione | |
| DE69716924D1 (de) | Phosphonat-nukleotid-verbindungen | |
| ID18685A (id) | Senyawa trisiklik tersubstitusi | |
| BR9707514A (pt) | Inibidor de neovascularizacão | |
| BR9705635A (pt) | Compostos | |
| DE69714228D1 (de) | Kristalline metallophosphate | |
| ATE353652T1 (de) | Östroprogestatives antikonzeptionsmittel | |
| BR9711205A (pt) | Composto | |
| PT923594E (pt) | Compostos de bromotiacumicina | |
| DE59708449D1 (de) | Substituierte p-trifluormethylphenyluracile | |
| DE69709659D1 (de) | Halopropargyl-einschlussverbindungen | |
| DE59707428D1 (de) | Substituierte 1-methyl-3-benzyluracile | |
| ATE275146T1 (de) | Substituierte pyrazol-3-ylbenzazole | |
| DE59708674D1 (de) | Substituierte 3-phenylpyrazole |